Your browser doesn't support javascript.
loading
Detection of circulating tumor DNA with ultradeep sequencing of plasma cell-free DNA for monitoring minimal residual disease and early detection of recurrence in early-stage lung cancer.
Tan, Aaron C; Lai, Gillianne G Y; Saw, Stephanie P L; Chua, Kevin L M; Takano, Angela; Ong, Boon-Hean; Koh, Tina P T; Jain, Amit; Tan, Wan Ling; Ng, Quan Sing; Kanesvaran, Ravindran; Rajasekaran, Tanujaa; Kalashnikova, Ekaterina; Renner, Derrick; Sudhaman, Sumedha; Malhotra, Meenakshi; Sethi, Himanshu; Liu, Minetta C; Aleshin, Alexey; Lim, Wan-Teck; Tan, Eng-Huat; Skanderup, Anders J; Ang, Mei-Kim; Tan, Daniel S W.
Affiliation
  • Tan AC; Division of Medical Oncology, National Cancer Centre Singapore, Singapore, Singapore.
  • Lai GGY; Duke-NUS Medical School, National University of Singapore, Singapore, Singapore.
  • Saw SPL; Division of Medical Oncology, National Cancer Centre Singapore, Singapore, Singapore.
  • Chua KLM; Duke-NUS Medical School, National University of Singapore, Singapore, Singapore.
  • Takano A; Division of Medical Oncology, National Cancer Centre Singapore, Singapore, Singapore.
  • Ong BH; Duke-NUS Medical School, National University of Singapore, Singapore, Singapore.
  • Koh TPT; Duke-NUS Medical School, National University of Singapore, Singapore, Singapore.
  • Jain A; Division of Radiation Oncology, National Cancer Centre Singapore, Singapore, Singapore.
  • Tan WL; Division of Pathology, Singapore General Hospital, Singapore, Singapore.
  • Ng QS; Duke-NUS Medical School, National University of Singapore, Singapore, Singapore.
  • Kanesvaran R; Department of Cardiothoracic Surgery, National Heart Centre Singapore, Singapore, Singapore.
  • Rajasekaran T; Division of Medical Oncology, National Cancer Centre Singapore, Singapore, Singapore.
  • Kalashnikova E; Duke-NUS Medical School, National University of Singapore, Singapore, Singapore.
  • Renner D; Division of Medical Oncology, National Cancer Centre Singapore, Singapore, Singapore.
  • Sudhaman S; Duke-NUS Medical School, National University of Singapore, Singapore, Singapore.
  • Malhotra M; Division of Medical Oncology, National Cancer Centre Singapore, Singapore, Singapore.
  • Sethi H; Duke-NUS Medical School, National University of Singapore, Singapore, Singapore.
  • Liu MC; Division of Medical Oncology, National Cancer Centre Singapore, Singapore, Singapore.
  • Aleshin A; Duke-NUS Medical School, National University of Singapore, Singapore, Singapore.
  • Lim WT; Division of Medical Oncology, National Cancer Centre Singapore, Singapore, Singapore.
  • Tan EH; Duke-NUS Medical School, National University of Singapore, Singapore, Singapore.
  • Skanderup AJ; Division of Medical Oncology, National Cancer Centre Singapore, Singapore, Singapore.
  • Ang MK; Duke-NUS Medical School, National University of Singapore, Singapore, Singapore.
  • Tan DSW; Natera, Inc, San Carlos, California, USA.
Cancer ; 130(10): 1758-1765, 2024 May 15.
Article in En | MEDLINE | ID: mdl-38422026
ABSTRACT

BACKGROUND:

In early-stage non-small cell lung cancer (NSCLC), recurrence is frequently observed. Circulating tumor DNA (ctDNA) has emerged as a noninvasive tool to risk stratify patients for recurrence after curative intent therapy. This study aimed to risk stratify patients with early-stage NSCLC via a personalized, tumor-informed multiplex polymerase chain reaction (mPCR) next-generation sequencing assay.

METHODS:

This retrospective cohort study included patients with stage I-III NSCLC. Recruited patients received standard-of-care management (surgical resection with or without adjuvant chemotherapy, followed by surveillance). Whole-exome sequencing of NSCLC resected tissue and matched germline DNA was used to design patient-specific mPCR assays (Signatera, Natera, Inc) to track up to 16 single-nucleotide variants in plasma samples.

RESULTS:

The overall cohort with analyzed plasma samples consisted of 57 patients. Stage distribution was 68% for stage I and 16% each for stages II and III. Presurgery (i.e., at baseline), ctDNA was detected in 15 of 57 patients (26%). ctDNA detection presurgery was significantly associated with shorter recurrence-free survival (RFS; hazard ratio [HR], 3.54; 95% confidence interval [CI], 1.00-12.62; p = .009). In the postsurgery setting, ctDNA was detected in seven patients, of whom 100% experienced radiological recurrence. ctDNA positivity preceded radiological findings by a median lead time of 2.8 months (range, 0-12.9 months). Longitudinally, ctDNA detection at any time point was associated with shorter RFS (HR, 16.1; 95% CI, 1.63-158.9; p < .0001).

CONCLUSIONS:

ctDNA detection before surgical resection was strongly associated with a high risk of relapse in early-stage NSCLC in a large unique Asian cohort. Prospective studies are needed to assess the clinical utility of ctDNA status in this setting.
Subject(s)
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Carcinoma, Non-Small-Cell Lung / Neoplasm, Residual / High-Throughput Nucleotide Sequencing / Circulating Tumor DNA / Lung Neoplasms / Neoplasm Recurrence, Local / Neoplasm Staging Limits: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Language: En Journal: Cancer Year: 2024 Type: Article Affiliation country: Singapore

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Carcinoma, Non-Small-Cell Lung / Neoplasm, Residual / High-Throughput Nucleotide Sequencing / Circulating Tumor DNA / Lung Neoplasms / Neoplasm Recurrence, Local / Neoplasm Staging Limits: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Language: En Journal: Cancer Year: 2024 Type: Article Affiliation country: Singapore